CT9.F CARDIOL THERAPEUTICS CL.A
- Market cap
- EUR 108M
- P/E
- -
- P/B
- 7.69x
- ROE
- -140.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CT9.F undervalued?
Graham numberThe Graham number of CARDIOL THERAPEUTICS CL.A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CARDIOL THERAPEUTICS CL.A fundamental analysis
No fundamental analysis for CARDIOL THERAPEUTICS CL.A yet.
CARDIOL THERAPEUTICS CL.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CARDIOL THERAPEUTICS CL.A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38,…
Full company profileCARDIOL THERAPEUTICS CL.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CARDIOL THERAPEUTICS CL.A annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 78.8K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -38.7M | -41.3M | -29.8M | -40.3M | -34.3M | -35.3M |
| EBITDA | - | -41.1M | -29.5M | -39.9M | -34.2M | -35.2M |
| Net Income | -31.6M | -30.9M | -28.1M | -36.7M | -33.8M | -33.8M |
| EPS | -0.51 | -0.48 | -0.43 | -0.44 | -0.34 | -0.29 |
| Balance Sheet | ||||||
| Total Assets | 87.9M | 62.0M | 36.7M | 31.9M | 23.6M | 29.4M |
| Total Liabilities | 11.6M | 9.83M | 8.45M | 7.14M | 5.74M | 5.33M |
| Shareholders' Equity | 76.2M | 52.2M | 28.2M | 24.7M | 17.9M | 24.0M |
| Cash & Short-term Investments | 83.9M | 59.5M | 34.9M | 30.6M | 21.4M | 26.1M |
| Cash Flow | ||||||
| Operating Cash Flow | -23.5M | -27.2M | -25.2M | -25.1M | -23.9M | -23.8M |
| Capital Expenditure | 12.9K | 74.7K | 64.3K | 21.3K | 24.5K | 101K |
| Free Cash Flow | -23.6M | -27.3M | -25.2M | -25.1M | -23.9M | -23.9M |
| Ratios | ||||||
| ROE | -41.5% | -59.3% | -99.6% | -148.3% | -189.2% | -140.7% |
| ROA | -36.0% | -49.9% | -76.6% | -115.1% | -143.2% | -115.1% |
| Net Profit Margin | -40,170.4% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CARDIOL THERAPEUTICS CL.A dividends
CARDIOL THERAPEUTICS CL.A has not paid dividends in the last 5 fiscal years.
Who owns CARDIOL THERAPEUTICS CL.A
- Insiders 2.22%
- Institutions 27.43%
- Public & others 70.35%
- Shares outstanding 122M
- Free float 92.0M
CARDIOL THERAPEUTICS CL.A company profile
- Company name
- CARDIOL THERAPEUTICS CL.A
- Ticker
- CT9.F
- ISIN
- CA14161Y2006
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 18
- Fiscal year end
- December
- Address
- 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
- Phone
- 289 910 0850
- Website
- cardiolrx.com
About CARDIOL THERAPEUTICS CL.A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
CARDIOL THERAPEUTICS CL.A management
5- Mr. David G. Elsley MBAPresident, CEO & Director
- Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBACFO, Corporate Secretary & Director
- Dr. Andrew Warwick Hamer M.D.Chief Medical Officer and Head of Research & Development · born 1962
- Trevor BurnsInvestor Relations
- Mr. John A. Geddes BSCPT, MBAVice President of Corporate Development